• 11059 Citations
  • 46 h-Index
1987 …2020
If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 1983 MD, College of Medicine, National Taiwan University

Research Interests

  • Cell Signaling Transduction
  • Nanomedicine
  • Oncology
  • Clinical Trial

Experience

  • 2004/08~now Professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University
  • 2017/08~now Director, Department of Internal Medicine, National Cheng Kung University Hospital
  • 2004/07~now Chief, Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital
  • 1990/08~now Attending Physician, National Cheng Kung University Hospital
  • 2011/10~2017/07 Director, Cancer Center, National Cheng Kung University Hospital
  • 2006/01~2011/09 Director, Clinical Trial Center, National Cheng Kung University Hospital

Fingerprint Dive into the research topics where Wu-Chou Su is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 21 Similar Profiles
Lung Neoplasms Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Mutation Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Taiwan Medicine & Life Sciences
Smoking Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1997 2020

Research Output 1987 2019

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

Lin, C. C., Arkenau, H. T., Lu, S., Sachdev, J., de Castro Carpeño, J., Mita, M., Dziadziuszko, R., Su, W-C., Bobilev, D., Hughes, L., Chan, J., Zhang, Z. Y. & Weiss, G. J., 2019 Jul 16, In : British Journal of Cancer. 121, 2, p. 131-138 8 p.

Research output: Contribution to journalArticle

Open Access
Lymphoma
Neoplasms
Safety
Non-Small Cell Lung Carcinoma
Maximum Tolerated Dose
2 Citations (Scopus)

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Yang, J. C. H., Gadgeel, S. M., Sequist, L. V. D., Wu, C. L., Papadimitrakopoulou, V. A., Su, W-C., Fiore, J., Saraf, S., Raftopoulos, H. & Patnaik, A., 2019 Mar 1, In : Journal of Thoracic Oncology. 14, 3, p. 553-559 7 p.

Research output: Contribution to journalArticle

Mutation
Therapeutics
Immunotherapy
pembrolizumab
gefitinib
23 Citations (Scopus)

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., Kubota, K., Lubiniecki, G. M., Zhang, J., Kush, D., Lopes, G., Gomez Aubin, G., Fein, L., Kaen, D., Kowalyszyn, R., Lerzo, G. & 236 others, Martinengo, G., Molina, M., Richardet, E., Picon, P., Varela, M., Zarba, J. J., de Azevedo, S. J., Barrios, C. H., Beato, C., Cerny, C. A. S., De Marchi, P. R. M., Fernandes, G., Franke, F. A., Freitas, H., Girotto, G., Lopes, V., Santos, L., Costa, M. A., Shimada, A. K., Smaletz, O., Soares, J. P. H., Victorino, A. P., Ferreira, C., Koleva, M., Koynov, K., Micheva, R., Deliverski, T., Milanova, Z., Doganov, B., Cheng, S., De Angelis, F., Speranza, G., Juergens, R. A., Ksienski, D., Fenton, D., Aren, O., Caglevic, C., Galindo, H., Rey, F., Chang, J., Chen, G., Chen, X., Ouyang, X., Cheng, Y., Ding, Z., Hou, M., Fan, Y., Feng, J., He, J., He, Y., Hu, Y., Li, W., Liu, X., Liu, Z., Lu, S., Qin, S., Tang, Q., Wang, B., Wang, K., Zhang, L., Zhang, X., Zhao, J., Wang, J., Zhou, C., Zhou, J., Zhou, Q., Wu, Y., Cardona, A., Duarte, R., Gomez Wolff, L., Zambrano, A., Vallejo, M., Havel, L., Kolek, V., Kolman, P., Koubkova, L., Petruzelka, L., Popelkova, P., Roubec, J., Vanasek, J., Vlasek, T., Jaal, J., Kuusk, G., Avendano, O., Castro, H., Lopez, K., Sandoval, M., Ho, C. M. J., Lo, S. H., Laczo, I., Piko, B., Ostoros, G., Aoe, K., Fujisaka, Y., Hirashima, T., Horiike, A., Hosomi, Y., Hotta, K., Ichiki, M., Imamura, F., Iwamoto, Y., Kasahara, K., Katakami, N., Kato, T., Murakami, S., Kawaguchi, T., Kishi, K., Kubota, K., Kurata, T., Torii, Y., Nakahara, Y., Nishimura, T., Ohira, T., Saka, H., Sawa, T., Seki, N., Sugawara, S., Takahashi, K., Takigawa, N., Tanaka, H., Yamada, K., Yokoyama, T., Yokoyama, T., Yoshioka, H., Kudaba, I., Purkalne, G., Stara, Z., Cesas, A., Cicenas, S., Zemaitis, M., How, S. H., Liam, C. K., Ong, C. K., Tho, L. M., Arrieta Rodriguez, O., de The Bustamante Valles, F., Hernandez Hernandez, C., Mas, L., Vera, L., Salas, J., Tejada, H., Edusma-Dy, R., Galvez, C., Ladrera, G. E. I., Tan Chun Bing, J., Jassem, J., Kalinka-Warzocha, E., Karaszewska, B., Kazarnowicz, A., Kowalski, D., Lesniewski Kmak, K., Ramlau, R., Araujo, A., Barata, F., Gil, N., Hespanhol, V., Alexandru, A., Dediu, M., Cherciu, N., Ciurescu, D., Ganea, D., Miron, L., Sirbu, D., Turdean, M., Emelyanov, S., Karaseva, N., Kuzina, L., Lazarev, S., Lifirenko, I., Bolotina, L., Lipatov, O., Ovchinnikova, E., Matrosova, M., Alyasova, A., Poltoratsky, A., Taranov, P., Zarubenkov, O., Cohen, G., Dreosti, L., Seolwane, F., Hall, J., Hart, G., Jordaan, C., Buddu, S., Botha, M., Landers, G., Rappaport, B., Ruff, P., Shepherd, L., Szpak, W., Ahn, M. J., Cho, B. C., Kim, J. H., Bergstrom, P., Ohman, R., Griph, H., Betticher, D., Ochsenbein, A., Zippelius, A., Chan, G. C., Chiu, C. H., Hsia, T. C., Su, W-C., Yang, C. H., Ativitavas, T., Danchaivijitr, P., Srimuninnimit, V., Seetalarom, K., Sookprasert, A., Sriuranpong, V., Altundag, O., Cay Senler, F., Erman, M., Goksel, T., Goker, E., Ozyilkan, O., Seker, M., Gumus, M., Turna, H., Yumuk, F., Adamchuk, G., Bondarenko, I., Ivashchuk, O., Ponomarova, O., Rusyn, A., Shevnya, S., Shparyk, Y., Sinielnikov, I., Andrusenko, O., Trukhyn, D., Ursol, G., Vynnychenko, I., Nguyen, T. Q., Pham, X. D., Castro, G. & Kubota, K., 2019 May 4, In : The Lancet. 393, 10183, p. 1819-1830 12 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Ligands
Drug Therapy
Neoplasms
Population
Open Access
Fluorodeoxyglucose F18
Non-Small Cell Lung Carcinoma
Glycolysis
Radiotherapy
Tumor Burden
9 Citations (Scopus)

Psychometric evaluation of the WHOQOL-BREF, Taiwan version, across five kinds of Taiwanese cancer survivors: Rasch analysis and confirmatory factor analysis

Lin, C. Y., Hwang, J. S., Wang, W. C., Lai, W-W., Su, W-C., Wu, T. Y., Yao, G. & Wang, J-D., 2019 Jan 1, In : Journal of the Formosan Medical Association. 118, 1P2, p. 215-222 8 p.

Research output: Contribution to journalArticle

Taiwan
Psychometrics
Statistical Factor Analysis
Survivors
Neoplasms

Thesis

Characterization of glycosylation patterns of interleukin-6 between non-small lung cancer cell lines and macrophage

Author: 婷卉, 黃., 2016 Feb 2

Supervisor: Su, W. (Supervisor)

Student thesis: Master's Thesis

Development of multifunctional FePt nanoparticle for targeted imaging agent and as a novel sensitizer for radiotherapy

Author: 婉莉, 施., 2016 Aug 30

Supervisor: Su, W. (Supervisor)

Student thesis: Master's Thesis

Studying mechanisms underlying ER-stress induction by LY294002@PLGA nanodrug

Author: 宜珊, 李., 2015 Feb 9

Supervisor: Su, W. (Supervisor)

Student thesis: Master's Thesis

The mechanism of vinorelbine-induced apoptosis and radiosensitization in lung cancer cells

Author: 威鑫, 邱., 2014 Aug 22

Supervisor: Su, W. (Supervisor)

Student thesis: Doctoral Thesis